GSK Reaffirms CIIE Resolve with Innovative Products, Solutions

Global biopharma firm GSK is participating in the 8th China International Import Expo, marking its eighth consecutive appearance.

Under the theme "Ahead Together," GSK showcases around 20 innovative products and solutions spanning respiratory, immunology and inflammation, infectious diseases, and oncology.

Covering 400 square meters, its booth also highlights an integrated approach to prevention and treatment across the healthcare lifecycle, underscoring the company's continued commitment to China's medical innovation and collaboration.

According to Sherman Yu, GSK vice president and GSK China general manager, this year's theme for the Medical Equipment and Healthcare Products Area, "Healthy China, Better Life," aligns perfectly with GSK's purpose for the CIIE.

"We are proud to be part of this remarkable journey and remain committed to contributing to a healthier future for China and the world," she said. "The CIIE is more than just an expo, it's a catalyst. It's a platform that amplifies opportunities, drives innovation, and strengthens connections. It transforms ideas into action and partnerships into progress."

At this year's CIIE, GSK spotlights liver and respiratory health as its two key focus areas.

For liver health, the company presents its pioneering Antisense Oligonucleotide (ASO) therapy, which shows potential for a functional cure for hepatitis B – underscoring its commitment to tackling liver disease in China through a full spectrum of prevention and treatment solutions.

In respiratory care, GSK continues to advance its portfolio of vaccines, biologics, and inhaled medicines to support personalized treatment. In February, China's drug regulator accepted GSK's new drug application for Nucala (mepolizumab) as an add-on maintenance therapy for chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

CIIE continues to amplify three key factors for global businesses – opportunities, innovation and connections. The expo signals China's commitment to high-level opening-up, allowing companies like GSK to be not only witnesses but active participants in the country's growth, said Yu.

It also serves as a global platform for innovation, where GSK has showcased cutting-edge healthcare solutions, including its ASO treatment for chronic hepatitis B, which has drawn wide attention.

Over 80 percent of GSK China's R&D projects are now integrated into global development programs. More than 60 percent of the product pipeline is dedicated to respiratory and immune diseases. And over 20 GSK clinical trials are under way in China, and within the next three years, it plans to launch about 18 new products and indications, including multiple "first-in-class" medicines and vaccines, to deliver transformative healthcare solutions for people in China.

In addition, the event strengthens connections through high-level forums and meetings. This year, GSK will join several closed-door sessions to share insights, explore partnerships and contribute to policy discussions advancing healthcare.

"This has brought a positive impact for GSK in three key areas: greater speed, stronger purpose, and sharper focus," said Yu.